Samsung Biologics Reports 10 Percent Increase in Q3 Net Profit to 264.5 Billion Won

SEOUL: Samsung Biologics Co. announced a 10 percent rise in its third-quarter net profit, reaching 264.5 billion won (US$191.3 million), compared to the same period last year. This growth aligns with the company's steady financial performance amid global economic fluctuations. According to Yonhap News Agency, the South Korean biopharmaceutical firm revealed through a regulatory filing that its operating income for the July-September period saw a 6.3 percent year-on-year increase, totaling 338.6 billion won. The company also reported a 14.8 percent rise in sales, amounting to 1.18 trillion won. The earnings surpassed market expectations, as analysts had predicted an average net profit of 251.3 billion won, based on a survey conducted by Yonhap Infomax, the financial data division of Yonhap News Agency. This strong financial performance underscores Samsung Biologics' robust operations and strategic market positioning.